Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8848397 | 0.80 | LTA4H (0.50) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL15022119 | 0.80 | ACACB (0.62) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL16330413 | 0.80 | BLM (0.65) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL7179523 | 0.80 | BLM (0.65) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL233225 | 0.80 | BLM (0.73) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL17285499 | 0.80 | BLM (0.73) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL29176455 | 0.79 | BLM (0.54) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL20825612 | 0.79 | BLM (0.54) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL22028548 | 0.79 | ACACB (0.41) | BLMGABRR1CYP1A2ACACBACACA | |
| SCHEMBL9001608 | 0.78 | ACE2 (0.64) | BLMGABRR1CYP1A2LTA4HACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674825-B2 | Dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | BAYER AKTIENGESELLSCHAFT | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058314-A1 | Novel dicarboxylic acid derivatives with pharmaceutical properties | PC, GOT2, SDHA | BLM 4429/4885GABRR1 1583/4885CYP1A2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.